Combining CPX-351 and ivosidenib for treating IDH1 mutated acute myeloid leukemia and high-risk myelodysplastic syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial evaluates the effectiveness of CPX-351, a chemotherapy drug, in combination with ivosidenib, a targeted therapy, for patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that have an IDH1 mutation. The study aims to determine the overall response rate to this treatment combination, assess its safety, and evaluate various time-to-event endpoints such as duration of response and overall survival. Patients will receive CPX-351 intravenously and ivosidenib orally over a specified treatment schedule, with the possibility of maintenance therapy for up to two years. The trial also includes exploratory objectives to evaluate biomarkers that may predict treatment response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
* IDH1-R132 mutated disease status as assessed by local laboratory. 2HG-producing IDH1 variants outside of R132 (i.e. R100) may be eligible after discussion with the principal investigator (PI)
* Treatment naive or relapsed/refractory AML who are eligible for intensive chemotherapy. Patients with high-risk MDS or MPN (defined as International Prognostic Scoring System Revised \[IPSS-R\] score ≥ 4 or dynamic \[D\]-IPSS ≥ 3) may also be eligible after discussion with the PI
* Adequate hepatic function (direct bilirubin ≤ 2 x upper limit of normal (ULN), Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 3 x ULN unless deemed to be related to underlying leukemia
* Adequate renal function including creatinine clearance ≥ 30 ml/min based on the Cockcroft-Gault equation.
* Willing and able to provide informed consent
* In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents.
* Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug

Exclusion Criteria:

* Patients who have previously received CPX-351.
* Patients with any concurrent uncontrolled clinically significant medical condition including infection, laboratory abnormality, or psychiatric illness, which could place the patient at unacceptable risk of study treatment.
* The use of other chemotherapeutic agents or anti-leukemic agents is not permitted during study with the following exceptions (1) intrathecal chemotherapy for prophylactic use or for controlled CNS leukemia. (2) use of hydroxyurea, and/or cytarabine (1 or 2 doses; up to 2 g/m2) for patients with rapidly proliferative disease is allowed before the start of study therapy.
* Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI).
* Patients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications.
* Patients with symptomatic congestive heart failure (NYHA Class III or IV), unstable angina, or an ejection fraction \< 45%.
* Patients with prior anthracycline exposure of \> 360 mg/m2 daunorubicin (or equivalent), or \> 210 mg/m2 daunorubicin (or equivalent) in patients with prior mediastinal radiation.
* QTc interval using Fridericia's formula (QTcF) \> 470 msec. A prolonged QTc interval in the setting of right bundle branch block is permitted after discussion with the PI.
* Nursing women, women of childbearing potential (WOCBP) with positive urine or serum pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception

  a. Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, IUD, and double barrier methods (for example a condom in combination with a spermicide).
* Subjects with a known medical history of progressive multifocal leukoencephalopathy (PML).
* Subjects taking strong CYP3A4 inducers are excluded from the study unless they can be transferred to other medications within ≥ 5 half-lives prior to dosing
* Patients with a diagnosis of acute promyelocytic leukemia (APL).
* Unresolved toxicities \> grade 1 from prior treatment including chemotherapy, targeted therapy, immunotherapy, experimental agents, radiation, or surgery.

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Courtney DiNardo, MD — M.D. Anderson Cancer Center
• Study coordinator: Courtney DiNardo, MD
• Email: cdinardo@mdanderson.org
• Phone: 713-794-1141

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using edetate calcium disodium or succimer to treat acute myeloid leukemia or myelodysplastic syndrome during chemotherapy

  This study is testing whether two drugs, edetate calcium disodium and succimer, can safely help people with acute myeloid leukemia or myelodysplastic syndrome feel better during chemotherapy.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT03630991

• Combining Ivosidenib and Venetoclax with or without Azacitidine for treating IDH1 mutated blood cancers

  This study is testing a combination of two drugs, ivosidenib and venetoclax, with or without azacitidine, to see if it helps people with certain types of blood cancers that have an IDH1 mutation.

  Recruiting at 4 sites Phase 1/2 M.D. Anderson Cancer Center · Boston, Massachusetts and 3 other locations · NCT03471260

• Total marrow and lymphoid irradiation with fludarabine and melphalan for older adults with refractory/relapsed AML or high-risk MDS undergoing donor stem cell transplant

  This phase 2 trial tests a targeted radiation conditioning (TMLI) with fludarabine and melphalan before a matched donor stem cell transplant in people aged 50 or older with difficult-to-treat AML or high-risk MDS.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07582172

• Testing a new anti-cancer drug for patients with acute myeloid leukemia and myelodysplastic syndromes

  This study is testing a new anti-cancer drug called cirtuvivint, alone and with another drug, to see if it helps people with acute myeloid leukemia and myelodysplastic syndromes feel better and live longer.

  Recruiting at 20 sites Phase 1 National Cancer Institute (NCI) · New Haven, Connecticut and 22 other locations · NCT06484062

• Combination treatment for FLT3-mutated acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a new combination of three drugs to see if it can help people with FLT3-mutated acute myeloid leukemia or high-risk myelodysplastic syndrome feel better and live longer.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05010122

• Using enasidenib and azacitidine to treat patients with recurrent or refractory acute myeloid leukemia and IDH2 gene mutation

  This study is testing if a combination of two medications, enasidenib and azacitidine, can help people with recurrent or hard-to-treat acute myeloid leukemia that has an IDH2 gene mutation.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03683433

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.